Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Swiss Exchange  >  Roche Holding AG    ROG   CH0012032048

ROCHE HOLDING AG

(ROG)
  Report
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Swiss Exchange
05/29/2020 06/02/2020 06/03/2020 06/04/2020 06/05/2020 Date
332.7(c) 334.85(c) 339.1(c) 332.75(c) 332.15(c) Last
2 770 053 2 618 991 1 770 787 2 935 576 1 970 444 Volume
-2.51% +0.65% +1.27% -1.87% -0.18% Change
More quotes
Financials
Sales 2020 62 739 M 65 174 M 65 174 M
Net income 2020 14 951 M 15 531 M 15 531 M
Net cash position 2020 2 284 M 2 373 M 2 373 M
P/E ratio 2020 19,0x
Yield 2020 2,83%
Sales 2021 64 531 M 67 034 M 67 034 M
Net income 2021 16 254 M 16 885 M 16 885 M
Net cash position 2021 11 397 M 11 839 M 11 839 M
P/E ratio 2021 17,5x
Yield 2021 2,93%
Capitalization 283 B 294 B 294 B
EV / Sales 2020 4,47x
EV / Sales 2021 4,21x
Nbr of Employees 97 735
Free-Float 83,7%
More Financials
Company
Roche Holding AG (Roche) is a research-based healthcare company. The Company's operating businesses are organized into two divisions: Pharmaceuticals and Diagnostics. The Pharmaceuticals Division consists of two business segments: Roche Pharmaceuticals and Chugai. The Diagnostics Division consists of four business areas: Diabetes Care, Molecular Diagnostics, Professional Diagnostics and Tissue Diagnostics. The... 
Sector
Pharmaceuticals
Calendar
06/09Presentation
More about the company
Surperformance© ratings of Roche Holding AG
Trading Rating : Investor Rating :
More Ratings
Latest news on ROCHE HOLDING AG
03:53aLonza picks Roche executive as CEO, ending year of turmoil at the top
RE
01:30aLonza Appoints Pierre-Alain Ruffieux as CEO
DJ
06/04GLOBAL MARKETS LIVE: LVMH buyer’s remorse, Amazon faces lawsuit…
06/04ROCHE : test receives FDA emergency use approval for COVID-19 patients
RE
06/04ROCHE : Elecsys IL-6 Test Receives FDA Emergency Use Authorization
DJ
06/04ROCHE : Elecsys IL-6 test receives FDA Emergency Use Authorisation to help in id..
AQ
06/02COMPULSORY LICENCES : The Key To Accessing Inventions In The Face Of Coronavirus..
AQ
06/02ROCHE : FDA approves Roche's Tecentriq in combination with Avastin for people wi..
AQ
06/02FDA approves Roche's Tecentriq in combination with Avastin for people with th..
GL
06/01CHUGAI PHARMACEUTICAL : Updated Data of Overall Survival and Safety from the ALE..
AQ
06/01Chugai Files Patent Infringement Lawsuit concerning Edirol Capsules against S..
AQ
06/01CHUGAI PHARMACEUTICAL : Obtains Approval for Expanded Use of FoundationOne CDx C..
AQ
06/01Chugai and FRONTEO Enter into a License Agreement for AI-based Drug Discovery..
AQ
06/01ROCHE HOLDINGS AG : Goldman Sachs gives a Buy rating
MD
05/29GENENTECH : FDA Approves Tecentriq in Combination With Avastin for Some Liver Ca..
DJ
More news
News in other languages on ROCHE HOLDING AG
01:33pROCHE CEO : le creux de la vague dû au coronavirus est passé
01:21pRoche-Chef sieht Tiefpunkt wegen Coronapandemie durchschritten
03:53aLonza picks Roche executive as CEO, ending year of turmoil at the top
03:40aSTOCK MARKET PARIS : Les valeurs à suivre à Paris et en Europe
01:38aSpezialchemiekonzern Lonza holt neuen Konzernchef von Roche
More news
Analyst Recommendations on ROCHE HOLDING AG
More recommendations
Stock Trading Strategies
ROCHE HOLDING AG - 04/17
Good timing to anticipate a continuation of the trend
BUY
More Stock Trading Analysis
Chart ROCHE HOLDING AG
Duration : Period :
Roche Holding AG Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends ROCHE HOLDING AG
Short TermMid-TermLong Term
TrendsBearishBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 23
Average target price 379,04 CHF
Last Close Price 332,15 CHF
Spread / Highest target 25,5%
Spread / Average Target 14,1%
Spread / Lowest Target -2,15%
EPS Revisions
Managers
NameTitle
Severin Schwan Chief Executive Officer & Executive Director
Christoph Franz Chairman
Alan Hippe Chief Financial & Information Technology Officer
Paul Bulcke Non-Executive Director
André S. Hoffmann Vice Chairman
Sector and Competitors
1st jan.Capitalization (M$)
ROCHE HOLDING AG5.97%296 065
JOHNSON & JOHNSON0.59%386 574
MERCK & CO., INC.-10.34%205 840
PFIZER, INC.-8.09%200 030
NOVARTIS AG-11.02%188 340
ABBVIE INC.5.08%163 968